McCoubrey, LE; Basit, AW; (2022) Addressing drug–microbiome interactions: the role of healthcare professionals. Pharmaceutical Journal , 308 (7958) pp. 1-27. 10.1211/PJ.2022.1.126780.

Preview

Text McCoubrey_Addressing drug–microbiome interactions_AAM.pdf Download (1MB) | Preview

Abstract

Growing evidence has highlighted the potentially significant impact of drug–microbiome interactions on patient care. It is possible that hundreds of drugs alter the composition of the microbiome, including many drugs with non-microbial targets. Drug-induced alteration of the microbiome could increase patients’ risk of dysbiosis, a state of microbiome unbalance that increases the chance of disease. Further, a drug’s pharmacokinetics and pharmacodynamics can be altered by the microbiome via direct (e.g. biotransformation or bioaccumulation) and indirect processes. Although these interactions are potentially important for patient health and therapeutic success, they are rarely considered during drug development or in clinical practice. Healthcare professionals working across sectors should consider drug–microbiome interactions to improve patient outcomes. This review provides an overview of the current evidence relating to drug–microbiome interactions, and describes how healthcare professionals working in clinical settings, academia, policy and drug development can immediately begin to address drug–microbiome interactions as an integral part of their roles.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item